Use of Continuous Glucose Monitoring and Insulin Pump Technologies in People With Type 2 Diabetes: Insights From a Survey of Health Care Professionals and Patients in Germany,Austria,and Switzerland

Abstract

Background:

Diabetes technologies, such as continuous glucose monitoring (CGM), insulin pumps, and automated insulin delivery (AID) systems, are increasingly used by people with type 2 diabetes (PWT2D), with growing clinical evidence supporting their therapeutic benefit. To describe the extent of adoption, perceived benefits, and future expectations, both health care professionals (HCPs) and PWT2D data from the dt-report 2025 were analyzed.

Methods:

From November to December 2025, HCP and PWT2D participated in the dt-report providing their attitudes, expectations, and predictions regarding the use of diabetes technology in type 2 diabetes. Frequencies from specific responses were analyzed.

Results:

Data from 1078 HCPs and 450 PWT2D from the DACH region were analyzed for questions regarding the use of technology in type 2 diabetes. Continuous glucose monitoring was the most widely endorsed technology across both groups, with 58% of the survey participants using a CGM, and 1% using a pump. Health care professionals estimated 87% of PWT2D on intensive insulin therapy would benefit from CGM and saw indications among non-intensive insulin users (62%) and those on oral therapies (55%). Future use of CGM and AID systems was anticipated by both HCPs and PWT2D, including many currently not using such systems. Smart pens and stand-alone insulin pumps were viewed less favorably. Reported barriers included lack of awareness, reimbursement limitations, digital literacy, and usability concerns.

Conclusion:

The findings indicate growing openness toward diabetes technologies among PWT2D and broader perceived indications among HCPs. However, uptake remains limited, particularly outside of intensive insulin therapy. These insights are of relevance for future clinical guidance, access strategies, and patient education.